[시장보고서]중저소득 국가용 오피오이드 대체요법 시장 - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

중저소득 국가용 오피오이드 대체요법 시장 - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

Low and Middle Income Countries Opioid Substitution Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

상품코드 : 1631257

리서치사 : Fairfield Market Research

발행일 : 2025년 01월

페이지 정보 : 영문 200 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,312,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495

￦ 12,436,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600

￦ 15,518,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

중저소득 국가용 오피오이드 대체요법(OST) 시장 규모는 연평균 7.20%의 CAGR로 2025년 8억 5,560만 달러에서 2032년 13억 9,100만 달러로 확대될 것으로 예상됩니다. OST는 불법 오피오이드를 메사돈이나 부프레노르핀과 같은 의학적으로 관리된 대체 약물로 대체함으로써 피해를 줄이고 개인의 중독 극복을 돕고, 과다복용, 혈액 매개 질환 전염 및 기타 합병증의 위험을 최소화하는 동시에 사회복귀를 돕습니다.

중저소득 국가에서 OST는 오피오이드 오남용과 관련된 공중보건 문제를 해결하는 데 필수적입니다. OST의 효과에 대한 인식 증가, 국제 및 정부 지원, 서비스 제공의 혁신이 시장 성장에 기여하고 있습니다. 시장 진입자에게는 문화적으로 적합한 OST 솔루션을 구축하기 위해 의료 서비스 제공자와 협력하고, 원격의료를 활용하여 의료 서비스가 부족한 지역에 대한 접근성을 확대할 수 있는 기회도 있습니다.

중저소득 국가용 오피오이드 대체요법 시장은 오피오이드 중독이 공중보건 문제로 인식되면서 지속적으로 성장하고 있습니다. 정부 및 국제기구의 지원은 OST 프로그램 시행을 촉진하고 있습니다. 시장 참여자들은 접근이 용이하고 지역 맞춤형 솔루션을 제공하기 위해 협력하고, 기술을 도입하여 환자들의 치료 결과를 개선함으로써 기회를 활용할 수 있습니다.

본 보고서는 중저소득 국가용 오피오이드 대체요법 시장에 대해 조사했으며, 시장 개요와 함께 약제 종류별, 적응증별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 정리하여 전해드립니다.

중저소득 국가용 오피오이드 대체요법 시장 전망, 약물 종류별, 규모(100만 달러), 수량(건), 2019-2032년
중저소득 국가용 오피오이드 대체요법 시장 전망, 적응증별, 규모(100만 달러), 수량(건), 2019-2032년
중저소득 국가용 오피오이드 대체요법 시장 전망, 유통 채널별, 규모(100만 달러), 수량(건), 2019-2032년
중저소득 국가용 오피오이드 대체요법 시장 전망, 지역별, 규모(100만 달러), 수량(건), 2019-2032년

제5장 북미의 중저소득 국가용 오피오이드 대체요법 시장 전망, 2019-2032년

제6장 유럽의 중저소득 국가용 오피오이드 대체요법 시장 전망, 2019-2032년

제7장 아시아태평양의 중저소득 국가용 오피오이드 대체요법 시장 전망, 2019-2032년

제8장 라틴아메리카의 중저소득 국가용 오피오이드 대체요법 시장 전망, 2019-2032년

제9장 중동 및 아프리카의 중저소득 국가용 오피오이드 대체요법 시장 전망, 2019-2032년

제10장 경쟁 구도

솔루션 유형별과 적응증별 히트맵
기업 시장 점유율 분석, 2024년
경쟁 대시보드
기업 개요
- Indivior Inc.
- Alkermes, Inc
- Mundipharma GmbH
- Viatris Inc
- Intas Pharmaceuticals
- Camurus

제11장 부록

ksm

영문 목차

영문목차

The global Low and Middle Income Countries Opioid Substitution Therapy (OST) Market is projected to grow at a CAGR of 7.20%, increasing from US$ 855.6 million in 2025 to US$ 1,391 million by 2032. OST involves replacing illicit opioids with medically supervised alternatives like methadone or buprenorphine, reducing harm and supporting individuals in overcoming addiction. OST minimizes risks of overdose, blood-borne disease transmission, and other complications while aiding reintegration into society.

In LMICs, OST is vital for addressing public health challenges linked to opioid misuse. The market's growth is fueled by rising awareness of OST's effectiveness, international and governmental support, and innovations in service delivery. Opportunities for market players include partnerships with healthcare providers to create culturally appropriate OST solutions and leveraging telemedicine to expand access in underserved areas.

The OST market in LMICs continues to grow due to increased recognition of opioid addiction as a public health concern. Government and international organization support has bolstered OST program implementation. Market players can capitalize on opportunities by collaborating to deliver accessible, region-specific solutions and incorporating technology to enhance patient outcomes.

Market Growth Drivers

1.Recognition of Public Health Impact

Governments and international health organizations increasingly recognize the burden of opioid addiction. This has led to proactive strategies, with OST emerging as a key harm reduction tool benefiting individuals and communities.

2.Policy Support and Collaboration

Collaborative efforts between governments, NGOs, and international organizations have promoted OST adoption. Supportive policies and integration into healthcare systems ensure broader program reach and impact.

3.Rising Awareness and Healthcare Investments

Increased awareness about opioid addiction and societal impacts, along with healthcare infrastructure investments, drive market growth. Advocacy campaigns promote harm reduction strategies and OST acceptance.

Market Restraints

1.Regulatory Challenges

Diverse regulatory frameworks across LMICs create significant hurdles. Variations in licensing, medication restrictions, and government support hinder OST adoption. Harmonizing regulations is critical for market growth.

2.Implementation Barriers

Limited healthcare infrastructure and insufficient provider training challenge effective OST deployment. Addressing these barriers requires capacity-building initiatives and strategic collaborations.

Business Opportunities

1.Telemedicine Expansion

Telemedicine can improve OST access in regions with limited healthcare infrastructure. Remote consultations and support services address geographical barriers, ensuring consistent care delivery.

2.Strategic Collaborations

Partnerships with healthcare providers, NGOs, and governments can enhance OST delivery. Collaborative efforts like training programs and awareness campaigns foster sustainable healthcare ecosystems.

3.Technological Innovations

Advanced OST solutions tailored to regional needs, such as digital tools for monitoring adherence, present growth potential. Investing in technology-driven systems can improve outcomes and expand market reach.

Regional Analysis

1.Europe

Europe leads the LMICs OST market with progressive harm reduction strategies and strong healthcare systems. Evidence-based policies and collaborations ensure widespread OST adoption. Europe's focus on personalized care and harm reduction establishes it as a model for managing opioid dependence effectively.

2.South Asia and the Pacific

South Asia and the Pacific is the fastest-growing region, driven by health policies and increasing public awareness. Government initiatives, international collaborations, and recognition of OST benefits position this region for rapid expansion.

3.Latin America, Middle East & Africa

Emerging markets in these regions offer untapped opportunities. Increased government efforts and growing investments in healthcare infrastructure drive OST adoption.

Competitive Analysis

Key players in the OST Market include:

Indivior Inc.
Alkermes, Inc.
Mundipharma GmbH
Viatris Inc.
Intas Pharmaceuticals
Camurus

These companies focus on innovation, collaborations, and targeted regional strategies to strengthen their market positions.

Low and Middle Income Countries Opioid Substitution Therapy Market Segmentation

1.By Drug Class

Opioid Antagonists
Naloxone
Naltrexone
Opioid Agonists and Partial Agonists
Methadone
Buprenorphine

2.By Indication

Pain Management
Opioid Withdrawal/Opioid Use Disorder (OUD)
Alcohol De-addiction
Depression

3.By Distribution Channel

Government-supported Centers/NGOs/Tenders
Institutional Sales
Hospitals
Psychiatric Clinics
Retail Pharmacies
Online Sales

4.By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

1. Executive Summary

1.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Economic Overview
- 2.6.1. World Economic Projections
2.7. PESTLE Analysis

3. Price Analysis, 2019 - 2023

3.1. Global Average Price Analysis by Drug Class, 2019 - 2023
3.2. Prominent Factor Affecting Low and Middle Income Countries Opioid Substitution Therapy Prices
3.3. Global Average Price Analysis by Region

4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

4.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 4.1.1. Key Highlights
  - 4.1.1.1. Opioid Antagonists
  - 4.1.1.2. Naloxone
  - 4.1.1.3. Naltrexone
  - 4.1.1.4. Opioid Agonists and Partial Agonists
  - 4.1.1.5. Methadone
  - 4.1.1.6. Buprenorphine
4.2. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 4.2.1. Key Highlights
  - 4.2.1.1. Pain Management
  - 4.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 4.2.1.3. Alcohol De-addiction
  - 4.2.1.4. Depression
4.3. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 4.3.1. Key Highlights
  - 4.3.1.1. Government-supported Centers/NGO's/Tenders
  - 4.3.1.2. Institutional Sales
  - 4.3.1.3. Hospitals
  - 4.3.1.4. Psychiatric clinics
  - 4.3.1.5. Retail Pharmacies
  - 4.3.1.6. Online Sales
4.4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Region, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 4.4.1. Key Highlights
  - 4.4.1.1. North America
  - 4.4.1.2. Europe
  - 4.4.1.3. Asia Pacific
  - 4.4.1.4. Latin America
  - 4.4.1.5. Middle East & Africa

5. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

5.1. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 5.1.1. Key Highlights
  - 5.1.1.1. Opioid Antagonists
  - 5.1.1.2. Naloxone
  - 5.1.1.3. Naltrexone
  - 5.1.1.4. Opioid Agonists and Partial Agonists
  - 5.1.1.5. Methadone
  - 5.1.1.6. Buprenorphine
5.2. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 5.2.1. Key Highlights
  - 5.2.1.1. Pain Management
  - 5.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 5.2.1.3. Alcohol De-addiction
  - 5.2.1.4. Depression
5.3. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 5.3.1. Key Highlights
  - 5.3.1.1. Government-supported Centers/NGO's/Tenders
  - 5.3.1.2. Institutional Sales
  - 5.3.1.3. Hospitals
  - 5.3.1.4. Psychiatric clinics
  - 5.3.1.5. Retail Pharmacies
  - 5.3.1.6. Online Sales
- 5.3.2. Attractiveness Analysis
5.4. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 5.4.1. Key Highlights
  - 5.4.1.1. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 5.4.1.2. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 5.4.1.3. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 5.4.1.4. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 5.4.1.5. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 5.4.1.6. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

6. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

6.1. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 6.1.1. Key Highlights
  - 6.1.1.1. Opioid Antagonists
  - 6.1.1.2. Naloxone
  - 6.1.1.3. Naltrexone
  - 6.1.1.4. Opioid Agonists and Partial Agonists
  - 6.1.1.5. Methadone
  - 6.1.1.6. Buprenorphine
6.2. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 6.2.1. Key Highlights
  - 6.2.1.1. Pain Management
  - 6.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 6.2.1.3. Alcohol De-addiction
  - 6.2.1.4. Depression
6.3. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 6.3.1. Key Highlights
  - 6.3.1.1. Government-supported Centers/NGO's/Tenders
  - 6.3.1.2. Institutional Sales
  - 6.3.1.3. Hospitals
  - 6.3.1.4. Psychiatric clinics
  - 6.3.1.5. Retail Pharmacies
  - 6.3.1.6. Online Sales
- 6.3.2. Attractiveness Analysis
6.4. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 6.4.1. Key Highlights
  - 6.4.1.1. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.2. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.3. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.4. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.5. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.6. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.7. France Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.8. France Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.9. France Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.10. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.11. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.12. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.13. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.14. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.15. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.16. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.17. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.18. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.19. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.20. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 6.4.1.21. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

7. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

7.1. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 7.1.1. Key Highlights
  - 7.1.1.1. Opioid Antagonists
  - 7.1.1.2. Naloxone
  - 7.1.1.3. Naltrexone
  - 7.1.1.4. Opioid Agonists and Partial Agonists
  - 7.1.1.5. Methadone
  - 7.1.1.6. Buprenorphine
7.2. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 7.2.1. Key Highlights
  - 7.2.1.1. Pain Management
  - 7.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 7.2.1.3. Alcohol De-addiction
  - 7.2.1.4. Depression
7.3. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 7.3.1. Key Highlights
  - 7.3.1.1. Government-supported Centers/NGO's/Tenders
  - 7.3.1.2. Institutional Sales
  - 7.3.1.3. Hospitals
  - 7.3.1.4. Psychiatric clinics
  - 7.3.1.5. Retail Pharmacies
  - 7.3.1.6. Online Sales
- 7.3.2. Attractiveness Analysis
7.4. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 7.4.1. Key Highlights
  - 7.4.1.1. China Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.2. China Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.3. China Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.4. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.5. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.6. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.7. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.8. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.9. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.10. India Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.11. India Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.12. India Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.13. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.14. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.15. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.16. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.17. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 7.4.1.18. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

8. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

8.1. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 8.1.1. Key Highlights
  - 8.1.1.1. Opioid Antagonists
  - 8.1.1.2. Naloxone
  - 8.1.1.3. Naltrexone
  - 8.1.1.4. Opioid Agonists and Partial Agonists
  - 8.1.1.5. Methadone
  - 8.1.1.6. Buprenorphine
8.2. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 8.2.1. Key Highlights
  - 8.2.1.1. Pain Management
  - 8.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 8.2.1.3. Alcohol De-addiction
  - 8.2.1.4. Depression
8.3. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 8.3.1. Key Highlights
  - 8.3.1.1. Government-supported Centers/NGO's/Tenders
  - 8.3.1.2. Institutional Sales
  - 8.3.1.3. Hospitals
  - 8.3.1.4. Psychiatric clinics
  - 8.3.1.5. Retail Pharmacies
  - 8.3.1.6. Online Sales
- 8.3.2. Attractiveness Analysis
8.4. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 8.4.1. Key Highlights
  - 8.4.1.1. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.2. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.3. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.4. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.5. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.6. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.7. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.8. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.9. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.10. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.11. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 8.4.1.12. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

9. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

9.1. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 9.1.1. Key Highlights
  - 9.1.1.1. Opioid Antagonists
  - 9.1.1.2. Naloxone
  - 9.1.1.3. Naltrexone
  - 9.1.1.4. Opioid Agonists and Partial Agonists
  - 9.1.1.5. Methadone
  - 9.1.1.6. Buprenorphine
9.2. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 9.2.1. Key Highlights
  - 9.2.1.1. Pain Management
  - 9.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  - 9.2.1.3. Alcohol De-addiction
  - 9.2.1.4. Depression
9.3. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 9.3.1. Key Highlights
  - 9.3.1.1. Government-supported Centers/NGO's/Tenders
  - 9.3.1.2. Institutional Sales
  - 9.3.1.3. Hospitals
  - 9.3.1.4. Psychiatric clinics
  - 9.3.1.5. Retail Pharmacies
  - 9.3.1.6. Online Sales
- 9.3.2. Attractiveness Analysis
9.4. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
- 9.4.1. Key Highlights
  - 9.4.1.1. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.2. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.3. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.4. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.5. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.6. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.7. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.8. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.9. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.10. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.11. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.12. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.13. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.14. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
  - 9.4.1.15. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

10. Competitive Landscape

10.1. By Solution Type vs by Indication Heatmap
10.2. Company Market Share Analysis, 2024
10.3. Competitive Dashboard
10.4. Company Profiles
- 10.4.1. Indivior Inc.
  - 10.4.1.1. Company Overview
  - 10.4.1.2. Product Portfolio
  - 10.4.1.3. Financial Overview
  - 10.4.1.4. Business Strategies and Development
- 10.4.2. Alkermes, Inc
  - 10.4.2.1. Company Overview
  - 10.4.2.2. Product Portfolio
  - 10.4.2.3. Financial Overview
  - 10.4.2.4. Business Strategies and Development
- 10.4.3. Mundipharma GmbH
  - 10.4.3.1. Company Overview
  - 10.4.3.2. Product Portfolio
  - 10.4.3.3. Financial Overview
  - 10.4.3.4. Business Strategies and Development
- 10.4.4. Viatris Inc
  - 10.4.4.1. Company Overview
  - 10.4.4.2. Product Portfolio
  - 10.4.4.3. Financial Overview
  - 10.4.4.4. Business Strategies and Development
- 10.4.5. Intas Pharmaceuticals
  - 10.4.5.1. Company Overview
  - 10.4.5.2. Product Portfolio
  - 10.4.5.3. Financial Overview
  - 10.4.5.4. Business Strategies and Development
- 10.4.6. Camurus
  - 10.4.6.1. Company Overview
  - 10.4.6.2. Product Portfolio
  - 10.4.6.3. Financial Overview
  - 10.4.6.4. Business Strategies and Development

11. Appendix

11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations